论文信息 - 23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064) - 字舞流文

23LBA An open-label, randomized, phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064)

C. Horak | R. Sullivan | J. Sosman | F. Hodi | G. Gibney | C. Slingluff | S. Nair | L. Fecher | D. Lawrence | L. Schuchter | J. Weber | E. Buchbinder | T. Logan | G. Kong | Mary M. Ruisi